169 related articles for article (PubMed ID: 15726649)
41. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
[TBL] [Abstract][Full Text] [Related]
42. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.
Haché G; Liddament MT; Harris RS
J Biol Chem; 2005 Mar; 280(12):10920-4. PubMed ID: 15647250
[TBL] [Abstract][Full Text] [Related]
43. Further investigation of simian immunodeficiency virus Vif function in human cells.
Gaddis NC; Sheehy AM; Ahmad KM; Swanson CM; Bishop KN; Beer BE; Marx PA; Gao F; Bibollet-Ruche F; Hahn BH; Malim MH
J Virol; 2004 Nov; 78(21):12041-6. PubMed ID: 15479843
[TBL] [Abstract][Full Text] [Related]
44. The inhibition of hepatitis B virus by APOBEC cytidine deaminases.
Janahi EM; McGarvey MJ
J Viral Hepat; 2013 Dec; 20(12):821-8. PubMed ID: 24304451
[TBL] [Abstract][Full Text] [Related]
45. Complementary function of the two catalytic domains of APOBEC3G.
Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
[TBL] [Abstract][Full Text] [Related]
46. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
47. A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.
Jeffrey Fessel W
Med Hypotheses; 2005; 64(2):261-3. PubMed ID: 15607551
[TBL] [Abstract][Full Text] [Related]
48. Rapid evolution of primate antiviral enzyme APOBEC3G.
Zhang J; Webb DM
Hum Mol Genet; 2004 Aug; 13(16):1785-91. PubMed ID: 15198990
[TBL] [Abstract][Full Text] [Related]
49. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
Kaiser SM; Emerman M
J Virol; 2006 Jan; 80(2):875-82. PubMed ID: 16378989
[TBL] [Abstract][Full Text] [Related]
50. Molecular characteristics and functional analysis of full-length hepatitis B virus quasispecies from a patient with chronic hepatitis B virus infection.
Cui XJ; Cho YK; Song HJ; Choi EK; Kim HU; Song BC
Virus Res; 2010 Jun; 150(1-2):43-8. PubMed ID: 20184927
[TBL] [Abstract][Full Text] [Related]
51. Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B.
Wurtzer S; Goubard A; Mammano F; Saragosti S; Lecossier D; Hance AJ; Clavel F
J Virol; 2006 Apr; 80(7):3679-83. PubMed ID: 16537639
[TBL] [Abstract][Full Text] [Related]
52. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors.
Gandhi SK; Siliciano JD; Bailey JR; Siliciano RF; Blankson JN
J Virol; 2008 Mar; 82(6):3125-30. PubMed ID: 18077705
[TBL] [Abstract][Full Text] [Related]
53. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G-->A hypermutation.
Günther S; Sommer G; Plikat U; Iwanska A; Wain-Hobson S; Will H; Meyerhans A
Virology; 1997 Aug; 235(1):104-8. PubMed ID: 9300041
[TBL] [Abstract][Full Text] [Related]
54. Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity.
Günther S; Paulij W; Meisel H; Will H
Virology; 1998 Apr; 244(1):146-60. PubMed ID: 9581787
[TBL] [Abstract][Full Text] [Related]
55. APOBEC3-induced mutation of the hepatitis virus B DNA genome occurs during its viral RNA reverse transcription into (-)-DNA.
Chen Z; Eggerman TL; Bocharov AV; Baranova IN; Vishnyakova TG; Patterson AP
J Biol Chem; 2021 Aug; 297(2):100889. PubMed ID: 34181944
[TBL] [Abstract][Full Text] [Related]
56. Expression of APOBEC3G in kidney cells.
Komohara Y; Suekane S; Noguchi M; Matsuoka K; Yamada A; Itoh K
Tissue Antigens; 2007 Jan; 69(1):95-8. PubMed ID: 17212712
[TBL] [Abstract][Full Text] [Related]
57. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
58. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.
De Mitri MS; Cassini R; Morsica G; Bagaglio S; Andreone P; Loggi E; Muratori P; Bernardi M
J Viral Hepat; 2006 Sep; 13(9):574-81. PubMed ID: 16907843
[TBL] [Abstract][Full Text] [Related]
59. APOBEC3G targets specific virus species.
Kobayashi M; Takaori-Kondo A; Shindo K; Abudu A; Fukunaga K; Uchiyama T
J Virol; 2004 Aug; 78(15):8238-44. PubMed ID: 15254195
[TBL] [Abstract][Full Text] [Related]
60. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.
Chen K; Huang J; Zhang C; Huang S; Nunnari G; Wang FX; Tong X; Gao L; Nikisher K; Zhang H
J Virol; 2006 Aug; 80(15):7645-57. PubMed ID: 16840343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
